News Release

Printer Friendly Version View printer-friendly version << Back
September 17, 2002 at 7:02 AM EDT

Quidel Corporation's QuickVue(R) Dipstick Strep A Test Receives Governmental Approval in Japan

SAN DIEGO, Sep 17, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that its QuickVue(R) Dipstick Strep A test received regulatory approval and a reimbursement code from the Japanese Ministry of Health and Welfare, allowing for the import of the test into Japan. This test will be sold by the Company's Japanese distributor, Sumitomo Seiyaku Biomedical Co., Ltd.

The QuickVue(R) Dipstick Strep A test is intended for use as an aid in the diagnosis of Group A Streptococcal infection, a common bacterial infection associated with "strep throat." Classic symptoms include the abrupt onset of sore throat, accompanied by fever, fatigue and headache. Left untreated, Group A Streptococcal infection can progress to complications such as rheumatic fever. This test is simple to use and provides results in 5 minutes or less in an easy to read two-color format. The QuickVue(R) Dipstick Strep A test is the newest addition to Quidel's family of rapid Strep A tests. The Company's other rapid Strep A tests include the CLIA-waived QuickVue(R) In-Line(R) Strep A and QuickVue(R)+ Strep A.

"Quidel's long-term business relationship with Sumitomo Seiyaku Biomedical provides a tremendous opportunity to further expand the QuickVue(R) brand into select worldwide markets," explains S. Wayne Kay, president and chief executive officer of Quidel. "By introducing the Dipstick Strep A test into the Japanese market, we further our goal to increase international revenues company-wide, while building on our recent successful launch of the RapidVue(R) Influenza test with Sumitomo in Japan."

"We look forward to expanding our successful relationship with Quidel into a new product market," said Noriaki Ohmura, Managing Director of Sumitomo Seiyaku BioMedical. "We feel this test will provide a valuable tool to quickly and effectively aid in the diagnosis and treatment of Group A Strep, and we anticipate strong demand for this rapid diagnostic."

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com .

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.

SOURCE Quidel Corporation

CONTACT: media, Bea Evangelista of Euro RSCG Middleberg, +1-212-699-2503, bea.evangelista@eurorscg.com; or investors, Ina McGuinness of Lippert/Heilshorn & Assoc., +1-310-691-7100, imcguinness@lhai.com, both for Quidel Corporation; or Paul E. Landers, Vice President & Chief Financial Officer of Quidel Corporation, +1-858-552-7962